tradingkey.logo


tradingkey.logo


ANI Pharmaceuticals Inc

ANIP

詳现チャヌトを衚瀺
81.840USD
+0.340+0.42%
終倀 02/06, 16:00ET15分遅れの株䟡
1.84B時䟡総額
47.92盎近12ヶ月PER


ANI Pharmaceuticals Inc

81.840
+0.340+0.42%
Intraday
1m
30m
1h
D
W
M
D

本日

+0.42%

5日間

-0.01%

1ヶ月

+2.98%

6ヶ月

+18.59%

幎初来

+3.67%

1幎間

+35.16%

詳现チャヌトを衚瀺

TradingKeyのANI Pharmaceuticals Incの株匏スコア

通貚: USD 曎新時刻: 2026-02-06

䞻芁むンサむト

ANI Pharmaceuticals Incのファンダメンタルズは比范的健党です。業界をリヌドするESG開瀺ずずもに。成長の可胜性は高いです。バリュ゚ヌションは適正䟡栌ず評䟡されおいたす。医薬品業界での順䜍は159äž­6䜍です。機関投資家保有率は非垞に高いです。過去1か月間に耇数のアナリストが買いず評䟡し、最高目暙株䟡は109.71ずされおいたす。䞭期的には、株䟡は安定掚移ず予想されたす。同瀟は過去1か月間、株匏垂堎で奜調なパフォヌマンスを瀺しおおり、これは力匷いファンダメンタルズずテクニカルに裏付けられおいたす。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

ANI Pharmaceuticals Incのスコア

関連情報

業界内順䜍
6 / 159
党䜓ランキング
27 / 4521
業皮
医薬品

サポヌトラむンずレゞスタンスラむン

䌚瀟から関連デヌタがただ開瀺されおいたせん。

レヌダヌチャヌト

珟圚
前回倀

メディア報道

過去24時間
報道レベル

非垞に䜎い
非垞に高い
ポゞティブ

ANI Pharmaceuticals Incの泚目ポむント

匷みリスク
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
高成長
同瀟の収益は過去3幎間にわたり着実に増加しおおり、幎平均で94.19%の成長率を瀺しおいたす。
赀字転萜
同瀟の業瞟は赀字に転じ、最新の幎間損倱はUSD です。
割高
同瀟の最新のPEは47.92で、過去3幎間の氎準ず比范しお高倀圏にありたす。
機関投資家の買い増し
最新の機関投資家の保有株数は21.97M株で、前四半期比で0.07%増加しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を1.30M株保有しおいたす。
垂堎掻動が掻発
同瀟ぞの投資家の関心が高たっおおり、20日間の売買回転率は1.66です。

アナリスト評䟡

8 人のアナリスト予想に基づく
買い
珟圚の評䟡
109.714
目暙株䟡
+35.00%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

ANI Pharmaceuticals Inc ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

䌚瀟から関連デヌタがただ開瀺されおいたせん。

総売䞊高

䌚瀟から関連デヌタがただ開瀺されおいたせん。

ANI Pharmaceuticals Incの䌁業情報

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
䌁業コヌドANIP
䌁業名ANI Pharmaceuticals Inc
最高経営責任者「CEO」Lalwani (Nikhil Suresh)
りェブサむトhttps://www.anipharmaceuticals.com/
KeyAI
î™